Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Dosing of the first patient in the Phase 1 clinical trial of ADCX-020.
-
Marvel Biosciences secures $600,000 in non-dilutive funding from Alberta Innovates to support Phase I clinical trials of its autism-focused patented MB-204
-
Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204, lead asset discovery, a patented neuroactive adenosine A2A antagonist
-
The Lancet Microbe publishes SNIPR001 Phase 1: safe, gut‑restricted, microbiome stable; Phase 1b HSCT trial >50% enrolled.
-
Synklino, publishes data in the American Journal of Transplantation and will present this as a poster at the Cutting Edge of Transplantation (CEoT) Summit.
-
PHILADELPHIA, Pennsylvania and COPENHAGEN, Denmark, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Alveus Therapeutics, Inc. (“Alveus”), a clinical-stage biotechnology company developing next-generation...
-
Agomab today announced positive interim results of the Phase 1 study of AGMB-447 in healthy participants.
-
TORONTO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- McEwen Inc. (NYSE/TSX: MUX) (“McEwen” or the “Company”) is pleased to announce that the extension of its Environmental Impact Assessment (Manifestación de...
-
Larkspur Biosciences announced the first participant has been dosed in the Phase 1 clinical study of its lead candidate, LRK-4189, in healthy volunteers.
-
LONDON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- TREOS Bio today announced the publication in Journal of Clinical Oncology - Oncology Advances of results from OBERTO-201 (NCT05130060), a Phase 1b study...